Innoviva Inc.: H.C. Wainwright raises price target after strong second-quarter results - Experts see 144% upside potential

Innoviva Inc. (INVA) has specialized in healthcare investments, focusing on royalties, intensive care, infectious diseases, and strategic investments. On August 5, the company presented its report for the second quarter. The company, which is a diversified holding company with a core business focus on royalties, a platform for intensive care and infectious diseases called Innoviva Specialty Therapeutics (IST), and a portfolio of strategic investments in healthcare, recorded a marginal revenue increase of 0.39% to $100.283 million, and a diluted...